Funding opportunities
Open and upcoming programs from Canadian funders and US federal grants (Grants.gov). Deadlines first, then rolling intakes.
Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
National Institutes of Health · Deadline not published
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies for cancer research or clinical care. The emphasis of this NOFO is on early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Well-suited applications must offer a high degree of technical innovation and the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, and/or epidemiology. Projects that are in-scope include technologies with new or significantly improved technical capabilities to measure, analyze, model, or interrogate cancer-related systems. These may include, but are not limited to, advanced molecular and cellular analysis platforms, multi-omic and spatial profiling methods, imaging and sensing technologies, immuno-engineering approaches, and innovations in biospecimen processing, modeling, and quality assessment. Technologies proposed for development may have potential for widespread applicability but must be f Awards up to $150,000.
NEA Arts and Artifacts Domestic Indemnity Program 2, FY2027 (6/27)
National Endowment for the Arts · Deadline 2027-06-07
See the application guidelines and instructions at arts.gov for more information. Awards range from $10,000 to $100,000.
Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Phase 2
National Institutes of Health · Deadline not published
NIDA seeks to further advance its mission in the area of single cell biology. Since 2020, the NIDA-funded Single Cell Opioid Responses in the Context of HIV (SCORCH) consortium has generated single-nucleus datasets from human and animal postmortem brain tissue under conditions of HIV infection, antiretroviral therapy (ART), and/or substance exposure (e.g. opioids, cocaine, methamphetamine, and cannabinoids). Building on this Phase 1 foundation, NIDA will encourage research addressing critical questions on Substance Use Disorder (SUD) and interactions with HIV disease progression at the subcellular, cellular, or circuit levels in the Central Nervous System (CNS). Many new cutting-edge single cell approaches (e.g. interrogation of RNA splicing, non-coding RNAs, epigenomic or proteomic features, subcellular or synaptic localization and function, spatial interactions, cell-cell communication, or cellular connectivity) now enable novel hypothesis-generating studies. Along with data mining studies to identify candidate mechanisms or targets contributing to HIV/SUD interactions and hypothesis-driven studies to assess functional significance, we expect SCORCH Phase 2 to significantly advan Awards up to $1,000,000.
Authority to Accept Unsolicited Proposals for Research Partnerships Notice of Intent (NOI)
Department of Housing and Urban Development · Deadline 2027-06-09
The U.S. Department of Housing and Urban Development"s Office of Policy Development and Research (PD&R) expects to release a Notice inviting eligible organizations to submit unsolicited research proposals focused on HUD"s current housing and community development research priorities. The goal of this Notice is to support independent, high-quality research that helps build reliable evidence and provides practical insights to inform housing policy and program decisions at the local, state, and Federal levels.Applicants will be expected to propose projects that align with the purpose of the program and at least one research category identified in the Notice. Projects must include matching funds equal to at least 50 percent of the total project cost, as required by statute. Awards are expected to be made as cooperative agreements, which means HUD will be actively involved throughout the project to help ensure the research is relevant, well designed, and aligned with Department priorities.PD&R expects to prioritize research on topics such as housing affordability, homelessness, industrialized housing production, Opportunity Zones, and outcomes related to work, family, and housing stabil
BRAIN Initiative: Development and Validation of Novel Tools and New Approaches for Neuroscience Research
National Institutes of Health · Deadline not published
The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for research to develop novel tools and approaches that enable the interrogation of cell-specific and circuit-specific processes in the central nervous system. This NOFO consolidates three current BRAIN Initiative tool development programs. Projects that focus on developing a broad range of new research tools to delineate anatomical and functional connections between cells and circuits, and to expand our knowledge of brain architecture and function are encouraged, such as projects that: Develop novel tools to characterize/define cell-types, circuits, and cellular components in the nervous system with greater selectivity and sensitivity, including: new genetic or non-genetic technologies/approaches (for delivering genes, proteins, and chemicals to access and/or manipulate cells of interest) novel sensors or tracers for imaging or monitoring molecules, structures, and activities within single cells and circuits with significant advances in sensitivity, selectivity, or spatiotemporal resolution Develop new technologies a
Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
National Institutes of Health · Deadline not published
NCI intends to release a Notice of Funding Opportunity (NOFO) that serves to continue the advancement and sustainment of informatics tools, software, and research resources that enable the acquisition, management, analysis, visualization, and interpretation of data across the cancer research continuum, including cancer biology, diagnosis and treatment, early detection, risk assessment and prevention, cancer control, and epidemiology. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this intended NOFO supports technologies that have progressed beyond initial prototyping and pilot development, demonstrate the potential for broad and significant impact in cancer research, and provide compelling reasons for further enhancement, optimization, dissemination, or sustainment. Awards up to $600,000.
Immune Drivers of Autoimmune Disease
National Institutes of Health · Deadline not published
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission through the continued support of the Immune Drivers of Autoimmune Disease (IDAD) network. This network aims to understand the earliest steps and triggers leading to autoimmunity and flare in humans, with the vision of ultimately preventing autoimmune disease. Priorities include discovering pre-clinical immune mechanisms, developing autoimmunity risk and staging prediction tools and biomarkers, building preclinical cohorts, leveraging remote recruitment and sampling, and artificial intelligence (AI)/big data. This complex, sustained collaboration relies on shared infrastructure to identify common triggers, pathways, and prevention opportunities. An Infrastructure Opportunity Fund (IOF) will be included in the initiative to provide the network the opportunity to conduct collaborative research projects. An IDAD Network Coordinating Center (NCC) will be responsible for administering the IOF and supporting additional coordinating activities amongst IDAD awardees, including the organization of Steering Committee meetings, resource sharing, data harmonization, sample sharing, and administering t
NIGMS National and Regional Resources (R24 - Clinical Trial Not Allowed)
National Institutes of Health · Deadline 2027-06-14
This Notice of Funding Opportunity (NOFO) encourages applications for support of resources that will provide access to state-of-the-art equipment, technologies, research tools, materials, organisms, software, and/or services to a substantial regional (multi-state) or national user base. Only those resources with technical capabilities that fall within the NIGMS-supported program areas are eligible for awards. The resources should already be established or may be formed through consolidation of existing local or regional facilities. The intent is to provide resource access to investigators without regard to the specific biomedical focus of their research, while not duplicating or replacing resources supported by sources such as other NIH Institutes and Centers (ICs) or host institutions. The resource is expected to be maintained or upgraded to current best practices, make its capabilities and availability known to the biomedical research community through a robust web presence and outreach activities, and provide user training and support.
BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed)
National Institutes of Health · Deadline 2027-06-15
This Notice of Funding Opportunity Announcement (NOFO) from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is intended to support establishment of facilities at minority-serving institutions (MSIs) and Institutional Development Award (IDeA)-eligible institutions for scaled production and distribution of brain cell type-specific access and manipulation reagents. Reagents will be initially developed in pilot resource projects for brain cell type-specific access and manipulation across vertebrate species from the BRAIN Initiative Armamentarium project. Awardees under this NOFO will work with the other Armamentarium awardees to manufacture and distribute the resources for use throughout the neuroscience community. It is envisioned that the awardees will work both with the Armamentarium community as well as with the neuroscience research community to optimize the use of new reagents. The types of reagents to be produced and distributed could include but are not limited to viral vectors, nucleic acid constructs, and nanoparticles designed for selective access to and manipulation of brain cell types. Such reagents will enable neuroscientists to pr
BRAIN Initiative: Brain Behavior Quantification and Synchronization- Next Generation Sensor Technology Development (U01 Clinical Trial Optional)
National Institutes of Health · Deadline 2027-06-15
This NOFO solicits applications for next generation sensor and bioelectronic device development that will synchronize with brain recordings. The sensor and neural recording data will be used to generate new computational models of behavior in human and animal models. There has been a lack of quantitative approaches and models to understand the complexity of human and animal behavior in naturalistic settings. This NOFO focuses on the development of next generation sensors to acquire data and synchronize it with simultaneous brain recordings to build computational models.
INCLUDE Project: Omics Phenotypes Related to Down Syndrome (X01 Clinical Trial Not Allowed)
National Institutes of Health · Deadline not published
The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications to submit samples to NIH INCLUDE Project-supported resources to generate a large volume of integrated genomic and multi-omics data that will facilitate discovery of the molecular mechanisms of health conditions related to Down syndrome. The resulting data, and associated clinical and phenotypic data, will become part of the INCLUDE Data Hub for sharing with the research community. No funding will be provided directly to applicants under this NOFO. Applicants are encouraged to propose omics assays of existing biospecimens collected from individuals with Down syndrome and controls.
Centers for Research on Neglected Infectious Diseases
National Institutes of Health · Deadline not published
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by supporting multidisciplinary research through the Centers for Research on Neglected Infectious Diseases (CReNIDs). Neglected infectious diseases (NIDs) comprise a diverse and understudied group of communicable viral, bacterial, parasitic, and fungal infections that cause substantial morbidity, mortality, and long-term health consequences worldwide. This new research program will emphasize the epidemiology, pathogenesis, diagnosis, treatment, and prevention of communicable parasitic NIDs in endemic regions and build sustainable in-country research capacity and expertise. The overarching goal is to protect and improve the health of the American people by strengthening US and global multidisciplinary research and training on NIDs to enable early identification, containment, and mitigation of infectious diseases at their sources, thereby reducing the risk of their spread to and within the United States. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regul
Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development
National Institutes of Health · Deadline not published
The NIH Blueprint for Neuroscience Research is interested in continuing to support the B lue P rint N eurotherapeutics Network for S mall M olecules (BPN-SM)- a program designed to help investigators advance promising small-molecule therapeutics toward clinical testing. The BPN-SM program supports drug discovery and development activities in investigators’ own laboratories while also providing access to NIH-supported subject matter experts and contract research organizations (CROs) with capabilities in medicinal chemistry, pharmacokinetics, toxicology, formulation development, GMP synthesis, and Phase I clinical testing. By integrating NIH resources with industry-standard expertise, BPN-SM advances investigator-initiated drug discovery while enabling investigators to retain and strengthen their intellectual property while gaining hands-on experience in translational drug development. The overarching goal of the program is to reduce the risk of scientific and therapy development sufficiently to enable external partners to take on late-stage development and ultimately bring new therapies to patients. In addition, this BPN program is specifically focused on small molecules and exclude
Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)
National Institutes of Health · Deadline 2027-06-17
The National Institute on Deafness and other Communication Disorders (NIDCD) intends to re-issue a Notice of Funding Opportunity (NOFO, prior funding opportunity RFA-DC-24-008 to solicit applications for research on early-stage dissemination and implementation (D&I) in the NIDCD mission areas of hearing, balance, taste, smell, voice, speech, and language. Much research is devoted to developing evidence-based innovations (EBIs) that improve a person"s health and quality of life. To impact people"s lives, EBIs need to be adopted in clinical practice and everyday life. Unfortunately, wide-scale adoption of EBIs is lengthy and rare. Dissemination and implementation (D&I) science is the field of research that seeks to close the gap between research and practice. Dissemination research is defined as the scientific study of the targeted distribution of information and materials about EBI to a specific audience (e.g., practitioners, patients, policymakers). The intent is to understand how best to communicate and integrate knowledge associated with a given EBI. Implementation Science refers to a broader array of active and planned efforts to integrate evidence into practice. Implementation
Limited Competition: BRAIN Initiative: Promoting Health for All Through BRAIN Technology Partnerships
National Institutes of Health · Deadline not published
The Brain Research Through Advancing Innovative Neurotechnologies® (BRAIN) Initiative, a collaboration of Federal and non-Federal partners led by NIH, intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications to accelerate the scientific impact and broad research adoption of BRAIN Initiative-relevant neurotechologies at institutions with limited NIH Research Project Grant funding. This opportunity will enable the integration of these neurotechnologies into the research and/or training programs of investigators at institutions with limited NIH Research Project Grant funding, while expanding the dissemination of BRAIN-initiative technologies. It is expected that these awards will support two-way knowledge transfer between the investigator and the BRAIN disseminator to enable novel, sustained integration of the neurotechnology into broader research practice. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Investigators with expertise and insights into this area of neuroscience resource dissemination are encouraged to begin to c
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
National Institutes of Health · Deadline not published
The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose pre-clinical and early-stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that aim to prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Through the NOFO, NIA is continuing the Alzheimer's Drug-Development Program (ADDP) with the aim of catalyzing drug development for AD. The ADDP is designed to provide funding support to academic and biotech researchers for preclinical drug development activities that can be conducted in their own laboratories or conducted in collaboration with contract research organizations that specialize in preclinical drug development activities. By supporting the most challenging and costly steps of drug development and seamlessly connecting preclinical drug development and first-in-human testing for drug candidates, the ADDP program seeks to: Continue to expand the number of investigational new drug candidates for a portfolio of emerging therapeutic targets; Continue to expand the therapeutic pipeline for AD with drug candidates targeti
Information Processing Techniques Office Office-Wide
DARPA - Information Processing Technologies Office · Deadline 2027-06-22
This Broad Agency Announcement (BAA) seeks revolutionary research ideas for topics not being addressed by ongoing IPTO programs or other published solicitations. Potential proposers are highly encouraged to visit the IPTO technical office page (https://www.darpa.mil/about/offices/ipto) to view current and upcoming IPTO programs and solicitations in order to avoid proposing efforts that duplicate existing activities or that are responsive to other published IPTO solicitations.
Tribal Epidemiology Centers
Indian Health Service · Deadline not published
Second cohort of TEC sites for any currently unserved Areas.
Somatic Mosaicism across Human Tissues (SMaHT) Program: Tissue Procurement Center (R24 Clinical Trial Not Allowed)
National Institutes of Health · Deadline not published
The purpose of the Somatic Mosaicism across Human Tissues (SMaHT) Network is to advance the discovery of biological processes and disease mechanisms mediated by somatic mutations in human tissues. Since 2023, the program has generated multi-omic somatic mutation datasets from a standardized set of human tissues spanning all three germ layers. Building on the Stage 1 foundation, the NIH intends to issue a Notice of Funding Opportunity (NOFO) seeking support for the SMaHT Tissue Procurement Center (TPC) initiative. The TPC will enable functional analyses of these healthy and clinically relevant tissue samples, providing critical resources to support characterization of somatic mosaicism and its role in human biology and disease. The Tissue Procurement Center will support the Network by collecting, processing, storing, and rapidly distributing high-quality, well-characterized human tissue specimens. Building on the 150 healthy donors enrolled during Stage 1, the TPC will procure tissues from at least 50 additional healthy donors, bringing the total to 200. The TPC will also collect up to 10 special tissue cohorts. The special tissue cohorts may include: tissues that can be grown in cu
Somatic Mosaicism across Human Tissues (SMaHT) Program: Genome Characterization Centers (UM1 Clinical Trial Not Allowed)
National Institutes of Health · Deadline not published
The purpose of the Somatic Mosaicism across Human Tissues (SMaHT) Network is to advance the discovery of biological processes and disease mechanisms mediated by somatic mutations in human tissues. Since 2023, the program has generated multi-omic somatic mutation datasets from a standardized set of human tissues spanning all three germ layers. Building on the Stage 1 foundation, the NIH intends to issue a Notice of Funding Opportunity (NOFO) seeking support for Stage 2 of the SMaHT Genome Characterization Centers (GCCs) initiative. The SMaHT Stage 2 GCCs will determine the functional consequences of somatic mutations in healthy and clinically relevant tissue samples, the latter comprising patients whose phenotype is suspected to be driven by somatic mutations. This work will support the SMaHT Network's efforts to characterize somatic mosaicism and its role in human biology and disease.